Jastreboff, Ania M.

Tirzepatide Once Weekly for the Treatment of Obesity

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 3,838

American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity

Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice

Clinical practice guidelines implementationObesity and Health Practices

Cited by 1,914

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 1,174

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 792

Stress as a Common Risk Factor for Obesity and Addiction

Sinha, R., & Jastreboff, A. M. (2013) · Biological Psychiatry

Regulation of Appetite and ObesityEating Disorders and Behaviors

Cited by 611

Tirzepatide for Obesity Treatment and Diabetes Prevention

Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 462

Obesity as a Disease: The Obesity Society 2018 Position Statement

Jastreboff, A. M., Kotz, C. M., Kahan, S., Kelly, A. S., & Heymsfield, S. B. (2019) · Obesity

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 457

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 423

Neural Correlates of Stress- and Food Cue–Induced Food Craving in Obesity

Jastreboff, A. M., Sinha, R., Lacadie, C., Small, D. M., Sherwin, R. S., & Potenza, M. N. (2013) · Diabetes Care

Regulation of Appetite and ObesityEating Disorders and Behaviors

Cited by 204

New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics

Jastreboff, A. M., & Kushner, R. F. (2023) · Annual Review of Medicine

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 158

Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial

Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., Ross, L., Liu, Y., Burns, C. E., Abbasi, S. A., et al. (2025) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 110

Altered brain response to drinking glucose and fructose in obese adolescents

Jastreboff, A. M., Sinha, R., Arora, J., Giannini, C., Kubat, J., Malik, S., Van Name, M. A., Santoro, N., Savoye, M., Duran, E. J., et al. (2016) · Diabetes

Regulation of Appetite and ObesityNeural and Behavioral Psychology Studies

Cited by 97

Leptin is associated with exaggerated brain reward and emotion responses to food images in adolescent obesity

Jastreboff, A. M., Lacadie, C., Seo, D., Kubat, J., Van Name, M. A., Giannini, C., Savoye, M., Constable, R. T., Sherwin, R. S., Caprio, S., et al. (2014) · Diabetes Care

Regulation of Appetite and ObesityEating Disorders and Behaviors

Cited by 83

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Dahl, K., Toubro, S., Dey, S., Duque do Vale, R., Flint, A., Gasiorek, A., Heydorn, A., Jastreboff, A. M., Key, C., Petersen, S. B., et al. (2025) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 80

Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder

Angarita, G. A., Matuskey, D., Pittman, B., Costeines, J. L., Potenza, M. N., Jastreboff, A. M., Schmidt, H. D., & Malison, R. T. (2021) · Drug and Alcohol Dependence

Neurotransmitter Receptor Influence on BehaviorSubstance Abuse Treatment and Outcomes

Cited by 75

Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO

Gaiser, E. C., Gallezot, J.-D., Worhunsky, P. D., Jastreboff, A. M., Pittman, B., Kantrovitz, L., Angarita, G. A., Cosgrove, K. P., Potenza, M. N., Malison, R. T., et al. (2016) · Neuropsychopharmacology

Neurotransmitter Receptor Influence on BehaviorRegulation of Appetite and Obesity

Cited by 59

Disordered Eating Behaviors in Emerging Adults With Type 1 Diabetes: A Common Problem for Both Men and Women

Doyle, E. A., Quinn, S. M., Ambrosino, J. M., Weyman, K., Tamborlane, W. V., & Jastreboff, A. M. (2017) · Journal of Pediatric Health Care

Eating Disorders and BehaviorsDiabetes Management and Education

Cited by 58

Preventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention: A Randomized Pilot Study

Jastreboff, A. M., Chaplin, T. M., Finnie, S., Savoye, M., Stults-Kolehmainen, M., Silverman, W. K., & Sinha, R. (2018) · The Journal of Pediatrics

Obesity, Physical Activity, DietMindfulness and Compassion Interventions

Cited by 57

Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial

Grilo, C. M., Lydecker, J. A., Jastreboff, A. M., Pittman, B., & McKee, S. A. (2023) · Obesity

Eating Disorders and BehaviorsPharmacology and Obesity Treatment

Cited by 47

Treating the Chronic Disease of Obesity

Gossmann, M., Butsch, W. S., & Jastreboff, A. M. (2021) · Medical Clinics of North America

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 33

Body mass index, metabolic factors, and striatal activation during stressful and neutral-relaxing states: An FMRI study

Jastreboff, A. M., Potenza, M. N., Lacadie, C., Hong, K. A., Sherwin, R. S., & Sinha, R. (2011) · Neuropsychopharmacology

Regulation of Appetite and ObesityNeurotransmitter Receptor Influence on Behavior

Cited by 32

Ending Weight Stigma to Advance Health Equity

Pearl, R. L., Donze, L. F., Rosas, L. G., Agurs-Collins, T., Baskin, M. L., Breland, J. Y., Byker Shanks, C., Cooksey Stowers, K., Johnson, S., Lee, B. Y., et al. (2024) · American Journal of Preventive Medicine

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 29

Sex differences in the association between dietary restraint, insulin resistance and obesity

Jastreboff, A. M., Gaiser, E. C., Gu, P., & Sinha, R. (2014) · Eating Behaviors

Eating Disorders and BehaviorsNutrition, Health and Food Behavior

Cited by 12